Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Johnson & Johnson confirmed on Monday, Jan. 8, that it is buying Ambrx cancer treatment developer Ambrx Biopharma for $2 billion. It will be paid in cash, and this acquisition deal comes as the company seeks to fill in a revenue gap expected to come in 2025 when its Stelara drug starts facing generic competition for treating an autoimmune disease called psoriasis.
Move to Diversify and Increase Revenues
According to CNBC, Johnson & Johnson announced the acquisition at the start of the annual JPMorgan Healthcare Conference. This move is seen as J&J’s entry into the ADC market that has recently been infiltrated by its rivals like Merck, Pfizer, and AbbVie, who have also acquired smaller drugmakers to bet on ADC.
The deal is a strategic decision since its top-selling Stelara drug is expected to face competition in the coming years. This means the company is preparing to produce new treatments that can provide revenues in case of a sales slowdown. The deal simply presents new opportunities for Johnson & Johnson, not only financially but also in having the chance to deliver new drugs that can transform cancer treatment and improve patients’ lives.
Terms of the Buyout Deal
As the agreement indicates, Johnson & Johson will pay $28 for every share of Ambrx or double the company’s Friday closing price, which was settled at $13.63. The New Brunswick, New Jersey-headquartered pharma and medical technologies company expects to complete the deal within the first two quarters of this year.
“Ambrx’s ADC technology offers unique advantages in the conjugation of stable antibodies and cytotoxic linker payloads, which results in engineered ADCs that effectively kill cancer cells and limit toxicities,” Johnson & Johnson Innovative Medicines’ area head of global therapeutic, Yusri A. Elsayed, M.D., M.H.Sc., Ph.D., said in a press release. “The results seen to date with ARX517 in mCRPC are promising and represent a potential first- and best-in-class targeted therapy for the treatment of this aggressive disease.”
The innovative medicine unit’s area leader for prostate cancer disease, Margaret Yu, M.D., further commented, “With a median overall survival of less than two years and novel hormonal therapies moving earlier in the disease, significant unmet need remains in the treatment of mCRPC, we see a unique opportunity to harness the potential of this innovative ADC platform, and with our deep understanding of prostate cancer, deliver a targeted PSMA therapeutic for addressing the growing needs of the more than 185,000 patients living with metastatic castration-resistant disease today1.”
Photo by: Johnson & Johnson Media Center
